Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
about
Immunogenicity of protein therapeutics: The key causes, consequences and challengesNovel Method for Radiolabeling and Dimerizing Thiolated Peptides Using (18)F-HexafluorobenzeneNanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.Non-invasive molecular imaging of prostate cancer lymph node metastasis.Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA).'Image and treat': an individualized approach to urological tumors89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.Pharmacokinetics and dosimetry of (111)In/(188)Re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models.Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.Functional imaging for prostate cancer: therapeutic implications.Prostate specific membrane antigen- a target for imaging and therapy with radionuclides.Developing imaging strategies for castration resistant prostate cancerNew horizons in prostate cancer imaging.Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer.Molecular imaging of urogenital diseases.Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models.The evolution of imaging in cancer: current state and future challenges.Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancerThe prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.High resolution digital autoradiographic and dosimetric analysis of heterogeneous radioactivity distribution in xenografted prostate tumors.PSMA PET and Radionuclide Therapy in Prostate Cancer.Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer.Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragmentOptimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry.[Imaging diagnostics of advanced prostate cancer].Molecular imaging of prostate cancer.
P2860
Q24633296-941564E8-B86E-4561-BB69-C2EE1D72DBC1Q28817842-A9D3C385-AB96-4FC1-8FC4-4DA5634EAA13Q30354652-718CACF2-CBB0-43AB-8F80-585ECD43A576Q33557567-AAC30C1E-67C7-4441-9EBD-6C2F7450988EQ33586706-717B9C74-817A-4B6D-B9F7-952389584574Q33792596-9FE30840-C196-40C6-AC23-2D51ABEABF01Q34389457-8F6B7AA2-4C6F-4647-8D41-F3959F6497F9Q35084128-FC20FD11-4E10-4063-9D8D-49A386FF8E2BQ35587920-4714DD12-B76F-4392-8EB0-DF1B2F6AB062Q36128629-5AA2E4EC-255A-438C-81E9-BD64A10FF0F9Q36135685-AF743036-0866-4126-9B53-E2037BD6120CQ36152211-91DE931E-EFE8-413F-8200-F7267C570B79Q37242030-020B84AA-37C4-4B78-849D-4F2ACD8E5760Q37457888-48FB5063-AC12-4DBC-AB35-B7F4B63CB669Q37550399-238D2BC6-F1E0-42D4-A5D7-7D9BE266341BQ37592073-2E472D42-8348-4813-8E67-EF613ACEA2E2Q37848518-6B4C607D-510C-44D7-9521-3F89191709E0Q37972920-A338D25D-0BD5-443A-A799-AE128C1A6868Q38169828-6EC07D1B-E0E0-4AD0-A65C-AD7489C354A1Q38190115-5125782E-0DA5-494B-893D-A44413AF78B7Q38728044-4E204793-9220-4DF8-8E65-03BA405853D3Q39003089-B50938D9-42AC-405C-AD38-FEE45910ED98Q39217780-B0724BB6-CABB-4D03-92A6-91732D4F6481Q39417962-3BF7CCAE-37EB-494B-B716-0CC9B8CF25FAQ39633289-87D141A4-4A46-4AD8-B9F7-5523882AFCE4Q39828822-3924F207-C88F-4435-B73E-D2C322452162Q40625131-E4027173-4219-4F0E-9399-D84771B37975Q40735810-61820C8C-A8C5-40A5-8971-D1FB4E89BCECQ42105089-C66E02FB-9B49-46C5-8642-A8EEE6B213EBQ53117553-486695D8-FBCF-481B-B8E3-2BC7B476815DQ53160549-DF568CCF-3E55-4154-9577-7FA5385F6CE8
P2860
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Antibody mass escalation study ...... ns for 90Y radioimmunotherapy.
@en
Antibody mass escalation study ...... ns for 90Y radioimmunotherapy.
@nl
type
label
Antibody mass escalation study ...... ns for 90Y radioimmunotherapy.
@en
Antibody mass escalation study ...... ns for 90Y radioimmunotherapy.
@nl
prefLabel
Antibody mass escalation study ...... ns for 90Y radioimmunotherapy.
@en
Antibody mass escalation study ...... ns for 90Y radioimmunotherapy.
@nl
P2093
P2860
P1476
Antibody mass escalation study ...... ns for 90Y radioimmunotherapy.
@en
P2093
Chaitanya R Divgi
Eze A Wills
Howard I Scher
Joseph A O'Donoghue
Lawrence H Schwartz
Mithat Gonen
Neeta Pandit-Taskar
Steven M Larson
P2860
P304
P356
10.2967/JNUMED.107.049502
P407
P577
2008-06-13T00:00:00Z